The Week

Eli Lilly (LLY) fell 2.93% this week to close at $1,115.70, down from $1,149.36 the previous Friday. The S&P 500 lost 0.8%, putting Lilly about 2.13 percentage points behind the benchmark. Across the four trading days from 8 to 11 September, the stock drifted lower from around $1,133 at the start of the week. Wednesday briefly touched $1,138.79 before fading, and Friday made a low of $1,113.292 before a small late recovery. The overall pattern was a choppy grind lower.

Key Events

The main company news this week was the closing of the AtaiBeckley acquisition. On 11 September Lilly confirmed the deal was complete, at a price of $3.8 billion, to advance therapies for treatment-resistant depression and other mental health conditions. AtaiBeckley had held its shareholder meeting on 9 September, reaching a quorum with 65.6% of shares represented. In parallel, Lilly said it plans to use profits from its GLP-1 franchise to fund women’s health initiatives, a topic that appeared in several reports during the week. On the industry side, a failed cholesterol drug trial at Novartis triggered a broad biopharma sell-off, and Lilly was caught in that pullback: the stock hit a one-month low in premarket and intraday trading on 8 September. Separately, Morgan Stanley cut Novo Nordisk, citing market share shifts toward Lilly and patent expiry risks.

Analyst Ratings

As of 11 September, 32 institutions cover Eli Lilly: 18 rate it buy, 6 rate it overweight, 4 rate it hold, 1 rates it underweight, 1 rates it sell, and 2 have no opinion. The consensus rating is buy. The consensus target price is $1,318.66, about 18.19% above the latest price, with a target range of $930 to $1,600 that points to wide disagreement. Among 206 names in the pharmaceutical industry, Lilly’s analyst rating rank is No. 1.

The Week Ahead

The US Empire State manufacturing index is due on 15 September, with a prior reading of 20.6 and a forecast of 14.75. On 16 September there is a heavier slate: US retail sales, retail sales ex-autos, import prices, the NAHB housing market index and EIA weekly crude inventories. For Lilly, the more meaningful date is 29 October, when it reports Q3 FY2026 results; consensus estimates are EPS of $9.2466 and revenue of $22.2 billion. Watch for any additional detail on AtaiBeckley integration or the women’s health push in the meantime.

In Short

Lilly’s share price was soft this week and lagged the market, but the company still had several business threads running: it closed the $3.8 billion AtaiBeckley deal and signalled plans to steer GLP-1 profits toward women’s health. On the analyst front, 24 of 32 covering institutions rate the stock buy or overweight, the consensus rating is buy, and the consensus target sits about 18.19% above spot, with Lilly ranked No. 1 in its industry; however, the target spread from $930 to $1,600 shows real divergence. On valuation, the stock trades around 39.32x P/E and 31x P/B, which is not cheap. The latest trading day’s fund flow showed small-lot and medium-lot flows pointing in opposite directions, reflecting a fairly scattered picture. The question now is whether the late-October earnings report can support growth expectations at the current valuation, and how quickly the sector recovers from the Novartis-driven sentiment hit.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.